Akebia Therapeutics Inc
AKBA3.700USD
-0.020-0.54%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
968.08MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Akebia Therapeutics Inc Unternehmen
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Unternehmensinformationen
BörsenkürzelAKBA
Name des UnternehmensAkebia Therapeutics Inc
IPO-datumMar 20, 2014
CEOMr. John P. Butler
Anzahl der mitarbeiter181
WertpapierartOrdinary Share
GeschäftsjahresendeMar 20
Addresse245 First Street
StadtCAMBRIDGE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02142
Telefon16178712098
Websitehttps://akebia.com/
BörsenkürzelAKBA
IPO-datumMar 20, 2014
CEOMr. John P. Butler
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
79.40K
+81.69%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
45.48K
-89.72%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
--
-100.00%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Jul 31
Aktualisiert: Thu, Jul 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
13.32%
Investment Advisor/Hedge Fund
10.58%
Hedge Fund
9.31%
Individual Investor
3.61%
Research Firm
2.48%
Private Equity
2.19%
Bank and Trust
0.14%
Pension Fund
0.04%
Insurance Company
0.03%
Other
58.30%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
281
109.59M
41.73%
+26.45M
2025Q1
280
111.54M
42.50%
+30.68M
2024Q4
258
78.54M
36.08%
+7.41M
2024Q3
257
64.16M
30.51%
-2.18M
2024Q2
248
61.31M
29.27%
-7.52M
2024Q1
290
61.37M
29.36%
-12.30M
2023Q4
289
58.79M
31.24%
-20.79M
2023Q3
300
57.28M
30.45%
-25.18M
2023Q2
308
56.18M
30.22%
-26.52M
2023Q1
315
56.14M
30.23%
-26.40M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
13.97M
5.32%
+133.23K
+0.96%
Mar 31, 2025
The Vanguard Group, Inc.
12.69M
4.83%
+1.80M
+16.55%
Mar 31, 2025
State Street Global Advisors (US)
6.81M
2.59%
+501.11K
+7.95%
Mar 31, 2025
Alerce Investment Management, L.P.
5.75M
2.19%
--
--
Dec 31, 2024
Satter Muneer A
5.75M
2.19%
+5.75M
--
Dec 31, 2024
Geode Capital Management, L.L.C.
5.03M
1.92%
+235.65K
+4.91%
Mar 31, 2025
Great Point Partners, LLC
4.97M
1.89%
+4.97M
--
Mar 31, 2025
Renaissance Technologies LLC
4.01M
1.53%
+182.30K
+4.77%
Mar 31, 2025
Citadel Advisors LLC
3.65M
1.39%
+2.26M
+163.86%
Mar 31, 2025
Franklin Advisers, Inc.
2.67M
1.02%
+2.50M
+1495.36%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ALPS Medical Breakthroughs ETF
0.65%
Invesco NASDAQ Future Gen 200 ETF
0.54%
Federated Hermes MDT Small Cap Core ETF
0.27%
SPDR S&P Biotech ETF
0.23%
iShares Micro-Cap ETF
0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.13%
iShares Russell 2000 Value ETF
0.06%
Global X Russell 2000 ETF
0.04%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil0.65%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.54%
Federated Hermes MDT Small Cap Core ETF
Anteil0.27%
SPDR S&P Biotech ETF
Anteil0.23%
iShares Micro-Cap ETF
Anteil0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.14%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.13%
Fidelity Enhanced Small Cap ETF
Anteil0.13%
iShares Russell 2000 Value ETF
Anteil0.06%
Global X Russell 2000 ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
